Photo from Yu Fujiwara/X
Aug 9, 2024, 17:56
Yu Fujiwara: ASCO Breakthrough to Highlight Advances in Esophageal, Nasopharyngeal, Lung Cancers
Yu Fujiwara, Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center, shared on X:
” ‘ASCO Breakthrough to Highlight Advances in Esophageal, Nasopharyngeal, Lung Cancers.’
Abstract 142 – IMRT vs CCRT for low risk nasopharyngeal ca, p3, OL, non-inferior trial, from China.
Really great to see a comparable result, supporting a de-escalation strategy for low risk nasopharyngeal ca.
With a median follow-up of 70.1 months, the IMRT-alone group had a similar 5-year overall survival (95.2% vs. 98.2%, hazard ratio, 2.27 [95%CI:0.70-7.40]; P=0.16), failure-free survival (86.2% vs. 88.4%, hazard ratio, 1.16 [95%CI:0.64-2.07]; p = 0.63).”
Read further.
Source: Yu Fujiwara/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14